Media coverage about Corcept Therapeutics (NASDAQ:CORT) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corcept Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.5318376883509 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Analysts assigned mean rating score of 2.00 for Corcept Therapeutics Incorporated (CORT) – Wall Street Morning (wallstreetmorning.com)
- A quick recap Technical data on Corcept Therapeutics Incorporated (CORT) – Wall Street Morning (wallstreetmorning.com)
- Corcept Therapeutics (CORT) Downgraded to Hold at BidaskClub (americanbankingnews.com)
- Investor’s Roundup (Intraday Analysis) – Corcept Therapeutics Incorporated (NASDAQ: CORT) – Alpha Beta Stock (alphabetastock.com)
- Corcept Therapeutics (CORT) Scheduled to Post Quarterly Earnings on Thursday (americanbankingnews.com)
Several research analysts have commented on the company. BidaskClub downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 7th. Stifel Nicolaus cut their target price on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, February 5th. Piper Jaffray Companies set a $30.00 target price on Corcept Therapeutics and gave the stock a “buy” rating in a report on Monday, February 5th. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $21.00.
Corcept Therapeutics (CORT) opened at $15.35 on Wednesday. The company has a market capitalization of $1,750.00, a PE ratio of 52.93 and a beta of 1.68. Corcept Therapeutics has a twelve month low of $8.14 and a twelve month high of $25.96.
In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $16.60, for a total transaction of $132,800.00. Following the transaction, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $132,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 24,000 shares of company stock worth $415,920 over the last ninety days. Company insiders own 19.20% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.